Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
20 June 2019Website:
http://www.atreca.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
regular market | Fri, 14 Jun 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
BCEL Latest News
Atreca (NASDAQ: BCEL ) stock is rising higher on Thursday following news of a major stake in the clinical-stage biopharmaceutical company from an investment advisor. According to a filing with the Securities and Exchange Commission (SEC), Baker Bros.
Atreca (BCEL) suspends the development of only pipeline candidate, ATRC-101, in clinical evaluation, as part of its business restructuring efforts and cuts headcount by 40%. The stock falls 37%.
Tech companies in certain high-growth sectors like semiconductors, AI, and cloud predominantly drove this year's bull market. But while these giants made headlines, many penny stocks continued trading at bargain prices.
Atreca, Inc. (NASDAQ:BCEL ) Q4 2022 Earnings Conference Call March 29, 2023 4:30 PM ET Company Participants Alex Gray - Head of Investor Relations John Orwin - CEO Tito Serafini - Chief Strategy Officer and Founder Philippe Bishop - Chief Medical Officer Stephen Gould - Chief Scientific Officer Herb Cross - Chief Financial Officer Conference Call Participants Divya Rao - Cowen Roger Song - Jefferies John Newman - Canaccord Tony Butler - EF Hutton Stephen Willey - Stifel Kemp Dolliver - Brookline Capital Operator Thank you for standing by. Welcome to the Atreca's Fourth Quarter and Year End 2022 Earnings Call.
Call/webcast to feature updates on the discovery platform and pipeline, including updated data from the ongoing Phase 1b trial of ATRC-101 Call/webcast to feature updates on the discovery platform and pipeline, including updated data from the ongoing Phase 1b trial of ATRC-101
What type of business is Atreca?
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. Atreca, Inc. was incorporated in 2010 and is based in San Carlos, California.
What sector is Atreca in?
Atreca is in the Healthcare sector
What industry is Atreca in?
Atreca is in the Biotechnology industry
What country is Atreca from?
Atreca is headquartered in United States
When did Atreca go public?
Atreca initial public offering (IPO) was on 20 June 2019
What is Atreca website?
https://www.atreca.com
Is Atreca in the S&P 500?
No, Atreca is not included in the S&P 500 index
Is Atreca in the NASDAQ 100?
No, Atreca is not included in the NASDAQ 100 index
Is Atreca in the Dow Jones?
No, Atreca is not included in the Dow Jones index
When does Atreca report earnings?
Next earnings report date is not announced yet